Insider Transactions in Q1 2021 at Veracyte, Inc. (VCYT)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 19
2021
|
Muna Bhanji Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,541
+50.0%
|
-
|
|
Mar 04
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
52,015
-7.08%
|
$2,652,765
$51.39 P/Share
|
|
Mar 04
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,970
+7.36%
|
$433,580
$14.98 P/Share
|
|
Mar 02
2021
|
Bonnie H Anderson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
6,320
-3.43%
|
$391,840
$62.15 P/Share
|
|
Mar 02
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,995
-7.42%
|
$371,690
$62.15 P/Share
|
|
Mar 02
2021
|
Keith Kennedy COO / CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,783
-4.72%
|
$358,546
$62.15 P/Share
|
|
Mar 02
2021
|
Mark Ho |
SELL
Payment of exercise price or tax liability
|
Direct |
490
-0.68%
|
$30,380
$62.15 P/Share
|
|
Feb 26
2021
|
Bonnie H Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+9.79%
|
-
|
|
Feb 26
2021
|
Iii James H Erlinger |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+50.0%
|
-
|
|
Feb 26
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+13.4%
|
-
|
|
Feb 26
2021
|
Keith Kennedy COO / CFO |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+10.9%
|
-
|
|
Feb 25
2021
|
Karin Eastham Director |
SELL
Open market or private sale
|
Direct |
6,250
-77.95%
|
$375,000
$60.96 P/Share
|
|
Feb 25
2021
|
Karin Eastham Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+50.0%
|
$25,000
$4.0 P/Share
|
|
Feb 24
2021
|
Bonnie H Anderson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
39,488
-19.38%
|
$2,448,256
$62.3 P/Share
|
|
Feb 24
2021
|
Keith Kennedy COO / CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,046
-9.31%
|
$684,852
$62.3 P/Share
|
|
Feb 24
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,048
-12.83%
|
$622,976
$62.3 P/Share
|
|
Jan 22
2021
|
Evan/ Fa Jones Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+14.29%
|
$10,000
$2.36 P/Share
|
|
Jan 20
2021
|
Mark Ho |
BUY
Exercise of conversion of derivative security
|
Direct |
52,500
+25.41%
|
$262,500
$5.7 P/Share
|
|
Jan 13
2021
|
Bonnie H Anderson Director |
SELL
Open market or private sale
|
Direct |
18,541
-4.25%
|
$927,050
$50.95 P/Share
|
|
Jan 13
2021
|
Bonnie H Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
18,541
+7.7%
|
$92,705
$5.61 P/Share
|
|
Jan 12
2021
|
Bonnie H Anderson Director |
SELL
Open market or private sale
|
Direct |
20,354
-3.08%
|
$1,017,700
$50.42 P/Share
|
|
Jan 12
2021
|
Bonnie H Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,354
+8.33%
|
$101,770
$5.61 P/Share
|
|
Jan 11
2021
|
Bonnie H Anderson Director |
SELL
Open market or private sale
|
Direct |
71,105
-9.43%
|
$3,555,250
$50.76 P/Share
|
|
Jan 11
2021
|
Bonnie H Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
71,105
+10.81%
|
$497,735
$7.24 P/Share
|
|
Jan 04
2021
|
Kevin K Gordon Director |
SELL
Open market or private sale
|
Direct |
10,000
-72.39%
|
$480,000
$48.95 P/Share
|
|
Jan 04
2021
|
Kevin K Gordon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$70,000
$7.39 P/Share
|